Trade Alert: Tripling Down
A rare, third entry on a high-conviction biotech from our Multibaggers list. Plus, bullish options bets on one a Portfolio Armor Top Name, and one from our Market Watchers list.
Three Trades From Three Sources
Today we’re drawing from three different engines of our research pipeline: Portfolio Armor’s Top Names, our Market Watchers X list, and our Multibaggers list.
If you’re new:
Top Names are generated daily by Portfolio Armor’s algorithm, which ranks thousands of securities by their estimated six-month returns and has more than doubled the return of the market since December of 2022.
Market Watchers is our curated list of accounts on X whose real-time reads on technicals, flows, macro, and sector rotations have proven early and accurate.
Multibaggers is a subset of our Market Watchers X list—analysts with documented 100%+ gainers over the last year.
We have one trade from each list today, and the final one is a rare third swing on a biotech setup with enough upside—and enough conviction—that it deserves another shot after two earlier entries.
A Quiet AI Play (Top Names)
Most AI-related stocks are loud about it. This one isn’t. It’s a European infrastructure company that’s quietly become a “picks-and-shovels” winner of the AI build-out—supplying the high-bandwidth routing, optical links, and data-center networking gear that make AI models actually usable at scale.
It’s already powering next-gen AI data centers, landing contracts with hyperscalers, and attracting strategic investment from one of the world’s most important AI chip companies. While everyone else debates GPU shortages, this name sits underneath the whole stack—and Portfolio Armor’s model now ranks it among the strongest six-month setups in the market.
Robotics Momentum (Market Watchers)
Yesterday we tried to place a trade on a small-cap robotics name showing up across our Market Watchers list—momentum, flows, and unusual options activity all pointed to an asymmetric setup. The bid never came to us, and as always, we refused to chase. We only take trades at fair prices.
Today, after repricing the structure and reassessing conditions (including its annual filing), we’re taking another swing. The long-term thesis remains the same: embodied AI and robotics adoption is inflecting, and this company is one of the purest ways to express that theme.
High-Conviction Biotech (Multibaggers)
Our Multibaggers analyst has been pounding the table on this one, and new information only strengthens the case. The company has a late-stage therapy where, according to our analyst, the FDA is no longer debating biology—it’s negotiating process. In his view, approval is not just likely but effectively inevitable, and it could arrive as soon as next month.
The last time this therapy received an initial greenlight, the stock exploded to prices more than triple where it trades now. If the drug gets a definitive approval this time, the move could be just as violent—and our options structure, with uncapped upside, is designed to magnify that.
This setup is strong enough that we’re taking the unusual step of adding a third swing today to maximize our exposure while maintaining disciplined, hedged structures.
Full details on all three trades below. Let’s make some money.
Today’s Top Names Trade
(Global connectivity / telecom rerating theme)
